JPH03251565A - Carbazole derivative - Google Patents
Carbazole derivativeInfo
- Publication number
- JPH03251565A JPH03251565A JP2044774A JP4477490A JPH03251565A JP H03251565 A JPH03251565 A JP H03251565A JP 2044774 A JP2044774 A JP 2044774A JP 4477490 A JP4477490 A JP 4477490A JP H03251565 A JPH03251565 A JP H03251565A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- compound
- piperidino
- carbazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 title claims description 4
- -1 trifluoromethylanilino Chemical group 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 12
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 abstract description 6
- 230000002490 cerebral effect Effects 0.000 abstract description 6
- PBDMLLFEZXXJNE-UHFFFAOYSA-N 2-carbazol-9-ylacetic acid Chemical compound C1=CC=C2N(CC(=O)O)C3=CC=CC=C3C2=C1 PBDMLLFEZXXJNE-UHFFFAOYSA-N 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 4
- 150000001412 amines Chemical class 0.000 abstract description 3
- 150000001716 carbazoles Chemical class 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 206010061216 Infarction Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- SOHAVULMGIITDH-ZXPSTKSJSA-N (1S,9R,14E)-14-(1H-imidazol-5-ylmethylidene)-2,11-dimethoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.01,13.03,8]hexadeca-3,5,7,10-tetraene-12,15-dione Chemical compound C([C@]1(C2=CC=CC=C2N([C@@]21NC1=O)OC)C(C)(C)C=C)=C(OC)C(=O)N2\C1=C\C1=CNC=N1 SOHAVULMGIITDH-ZXPSTKSJSA-N 0.000 description 1
- SEYQGVYTVHINPB-UHFFFAOYSA-N 2,3-dimethoxyfuran Chemical compound COC=1C=COC=1OC SEYQGVYTVHINPB-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- SOHAVULMGIITDH-UHFFFAOYSA-N Oxaline Natural products O=C1NC23N(OC)C4=CC=CC=C4C3(C(C)(C)C=C)C=C(OC)C(=O)N2C1=CC1=CN=CN1 SOHAVULMGIITDH-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LNGTVJADQVHFHN-UHFFFAOYSA-N ethyl 2-carbazol-9-ylacetate Chemical compound C1=CC=C2N(CC(=O)OCC)C3=CC=CC=C3C2=C1 LNGTVJADQVHFHN-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- UICBCXONCUFSOI-UHFFFAOYSA-N n'-phenylacetohydrazide Chemical compound CC(=O)NNC1=CC=CC=C1 UICBCXONCUFSOI-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は、過酸化脂質生成抑制作用及び脳保護作用を有
するカルバゾール誘導体に関する。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to carbazole derivatives having lipid peroxide production inhibiting activity and brain protective activity.
良釆り弦オ
過酸化脂質は、膜や酵素の変性を惹起して細胞の障害や
機能低下をもたらし、心筋硬泰や脳硬璽をはじめとする
動脈硬化性疾患、肝疾患、肺浮腫、皮膚疾患、眼疾患な
どの種々の疾患や老化との関連が知られている。また、
過酸化脂質抑制剤は、脳の血管障害による脳細胞の虚血
状態が生じた場合、脳血管拡張作用によって血流量を増
加させ、脳内に酸素を供給し、脳内の酸素欠乏状態を改
善し、さらに、細胞内アデノシン三リン酸の有効利用を
促すことにより細胞死を防ぐ。Lipid peroxides cause denaturation of membranes and enzymes, leading to cell damage and functional decline, leading to arteriosclerotic diseases such as myocardial stiffness and cerebral stiffness, liver disease, pulmonary edema, It is known to be associated with various diseases such as skin diseases and eye diseases, and with aging. Also,
Lipid peroxide inhibitors increase blood flow through cerebral vasodilation when brain cells are in an ischemic state due to cerebral vascular disorder, supplying oxygen to the brain and improving the oxygen deficient state in the brain. Furthermore, it prevents cell death by promoting the effective use of intracellular adenosine triphosphate.
過酸化脂質抑制作用、脳循環改善作用、脳代謝促進作用
を有する薬剤としては、たとえばビンポセチン(神経精
神薬理、第7巻、第113頁、 1985年)、イデベ
ノン(薬理と治療、第13巻、第673頁、 1985
年)などが知られている。一方、本発明の化合物の構造
に近似の化合物としては9−(N。Examples of drugs that suppress lipid peroxide, improve cerebral circulation, and promote cerebral metabolism include vinpocetine (Neuropsychopharmacology, Vol. 7, p. 113, 1985), idebenone (Pharmacology and Treatment, Vol. 13, No. 673, 1985
) are known. On the other hand, a compound having a structure similar to that of the compound of the present invention is 9-(N.
N−ジメチルアミノカルボニルメチル
ゾールが知られているが、上記の作用については報告き
れていない。Although N-dimethylaminocarbonylmethylzole is known, the above effects have not been fully reported.
明が 決しようとする課題
本発明の目的は、過酸化脂質抑制及び脳保護作用を有す
る化合物を提供することにある。DISCLOSURE OF THE INVENTION An object of the present invention is to provide a compound that suppresses lipid peroxide and protects the brain.
課題を解決するための手段
本発明者らは、カルバゾール骨格を有する化合物につい
て鋭意検討した結果、過酸化脂質抑制作用および脳保護
作用を有する新規のカルバゾール誘導体を見出し本発明
を完成した。Means for Solving the Problems As a result of intensive studies on compounds having a carbazole skeleton, the present inventors discovered a new carbazole derivative having lipid peroxide suppressing action and brain protective action, and completed the present invention.
本発明は、式I
[式中、Rは、1−ピロリジノ基、1−ピペリジノ基、
低級アルキル基で置換きれた1−ピペリジノ基、1−ピ
ペラジノ基、1−モルホリノ基またはトリフルオロメチ
ルアニリノ基を示す、]で表わされるカルバゾール誘導
体である。The present invention relates to the formula I [wherein R is a 1-pyrrolidino group, a 1-piperidino group,
It is a carbazole derivative represented by ], which represents a 1-piperidino group, a 1-piperazino group, a 1-morpholino group, or a trifluoromethylanilino group substituted with a lower alkyl group.
本発明において、低級アルキル基とは、R素数1〜4の
直鎖状または分枝鎖状のアルキル基であり、それらはメ
チル基、プロピル基、イソプロピル基、ブチル基、イソ
ブチル基、t−ブチル基である。In the present invention, a lower alkyl group is a linear or branched alkyl group having an R prime number of 1 to 4, and these include a methyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, and a t-butyl group. It is the basis.
式Iの化合物は種々の方法にて製造できるが、たとえば
、次の方法で製造できる。The compound of formula I can be produced by various methods, for example, by the following method.
まず、カルバゾールとα−ハロゲン酢酸アルキルエステ
ルを塩基の存在下、有機溶媒中で反応きせることにより
9−アルコキシカルボニルメチルカルバゾールとする。First, carbazole and α-halogen acetic acid alkyl ester are reacted in an organic solvent in the presence of a base to produce 9-alkoxycarbonylmethylcarbazole.
本反応における塩基とは水素化ナトリウム、水素化カリ
ウム、t−ブトキシカリウム、次階ナトリウム、戻酸カ
リウム、水酸化ナトリウム、水酸化カリウムなどであり
、有機溶媒とはN、N−ジメチルホルムアミド、ジメチ
ルスルフオキシド、テトラヒドロフラン、アセトン、ジ
メトキシフラン、N−メチルピロリドンなどである。The bases used in this reaction include sodium hydride, potassium hydride, t-butoxypotassium, secondary sodium, potassium rehydrate, sodium hydroxide, potassium hydroxide, etc., and the organic solvents include N,N-dimethylformamide, dimethyl These include sulfoxide, tetrahydrofuran, acetone, dimethoxyfuran, and N-methylpyrrolidone.
次イで、上記で得られた9−アルコキシカルボニルメチ
ルカルバゾールを、水酸化ナトリウム、水酸化カリウム
などを用いた通常の加水分解により9−カルボキシメチ
ルカルバゾール
次いで、これと式R−H(式中、Rは前記と同意義であ
る。)で表わ芒れるアミン類を、反応に不活性な溶媒中
、縮合剤および塩基性化合物の存在下または不存在下反
応させることにより本発明化合物を得ることができる。In the next step, the 9-alkoxycarbonylmethylcarbazole obtained above is subjected to conventional hydrolysis using sodium hydroxide, potassium hydroxide, etc. to give 9-carboxymethylcarbazole and the formula R-H (in the formula, The compound of the present invention can be obtained by reacting amines represented by (R has the same meaning as above) in a solvent inert to the reaction in the presence or absence of a condensing agent and a basic compound. I can do it.
本反応において、反応に不活性な溶媒とは、たとえばベ
ンゼン、クロロホルム、塩化メチレン、テトラヒドロフ
ラン、N.N−ジメチルホルムアミド、水など、または
これらの混合物であり、縮合剤とは、たとえばシアノリ
ン酸ジエチル、N.N−ジシクロヘキシルカルボンジイ
ミド、ジフェニルホスホリルアジド、亜リン酸トリアル
キルエステル、三塩化リン、オキザリンクロリドなどで
ある。塩基性化合物とは、たとえばピリジン、トリエチ
ルアミン、水酸化ナトリウム、水酸化カリウム、戻酸ナ
トリウム、次階カリウム、水素化ントリウムなどである
。反応終了後、通常、水を加えると結晶が析出し、濾過
により目的物を得ることができる。また、結晶が析出し
ない場合には、適当な溶媒(たとえば、ベンゼン、クロ
ロホルム、酢酸エチルナど)で抽出し、以下常法により
処理して本発明化合物を得ることができる。In this reaction, solvents inert to the reaction include, for example, benzene, chloroform, methylene chloride, tetrahydrofuran, N.I. N-dimethylformamide, water, etc., or a mixture thereof, and the condensing agent is, for example, diethyl cyanophosphate, N-dimethylformamide, water, etc. These include N-dicyclohexylcarbondiimide, diphenylphosphoryl azide, phosphorous acid trialkyl ester, phosphorus trichloride, and oxaline chloride. Examples of the basic compound include pyridine, triethylamine, sodium hydroxide, potassium hydroxide, sodium rehydrate, potassium hydroxide, and thorium hydride. After the reaction is completed, crystals are usually precipitated by adding water, and the desired product can be obtained by filtration. In addition, when crystals do not precipitate, the compound of the present invention can be obtained by extraction with a suitable solvent (eg, benzene, chloroform, ethyl acetate, etc.) and subsequent treatment by a conventional method.
また、本発明化合物は、9−力ルポキシメチル力ルバゾ
ールを塩化チオニルなどにより酸クロリドとし、これに
前記アミン類を反応許せても得ることができる。The compound of the present invention can also be obtained by converting 9-rupoxymethyl-rubazole into an acid chloride using thionyl chloride or the like, and allowing the above-mentioned amines to react with the acid chloride.
発明の効果
本発明により、過酸化脂質抑制作用及び脳保護作用を有
する化合物が提供きれた。Effects of the Invention According to the present invention, a compound having lipid peroxide suppressing action and brain protective action has been provided.
犬蓋忽
次に実施例により、本発明化合物の製造法を更に詳細に
説明する。Next, the method for producing the compound of the present invention will be explained in more detail with reference to Examples.
実施例
(1)窒素気流下、60%水素化ナトリウム2. 63
gとジメチルスルホキシド30mQを60℃で1時間
攪拌し、水冷後、カルバゾール10gの無水テトラヒド
ロフラン80mlを加え、室温で30分間攪拌した。Example (1) 60% sodium hydride under nitrogen flow2. 63
After cooling with water, 10 g of carbazole and 80 ml of anhydrous tetrahydrofuran were added, and the mixture was stirred at room temperature for 30 minutes.
次いで、ブロモ酢酸エチル10. 5 gの無水テトラ
ヒドロフラン40m1溶液を水冷下加え、室温で11時
間攪拌した0反応液に水を加え、酢酸エチルで抽出し、
水洗、乾燥後、ツタノールより再結晶して9エトキシカ
ルボニルメチルカルバゾールを得た。Then ethyl bromoacetate 10. A solution of 5 g of anhydrous tetrahydrofuran (40 ml) was added under water cooling, and the mixture was stirred at room temperature for 11 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
After washing with water and drying, it was recrystallized from tutanol to obtain 9-ethoxycarbonylmethylcarbazole.
m. p. 94〜95. 5°C
(2) 9−エトキシカルボニルメチルカルバゾールタ
ノール100mlの混液に入れ、2時間加熱還流した。m. p. 94-95. 5°C (2) The mixture was added to a mixture of 100 ml of 9-ethoxycarbonylmethylcarbazoletanol and heated under reflux for 2 hours.
冷後、濃塩酸で酸性とし、析出した結晶を濾取、水洗、
乾燥後、クロロホルムより再結晶してして9−カルボキ
シメチルカルバゾール得た。After cooling, acidify with concentrated hydrochloric acid, collect the precipitated crystals by filtration, wash with water,
After drying, it was recrystallized from chloroform to obtain 9-carboxymethylcarbazole.
11、1)、 190〜191℃
(3) 窒素気流下、9−カルボキシメチルカルバゾー
ル5gとピロジン1.74gをジメチルホルムアミド4
0mlに溶かし、これにシアノリン酸ジエチル3、 5
3 gのN.N−ジメチルホルムアミド15ml溶液を
加え、次いでトリエチルアミン4. 19 gを加え、
14時間室温で攪拌した。混合物に水を加え、酢酸エチ
ルで抽出した。5%塩酸溶液、次階水素ナトリウム水溶
液および飽和食塩水の順で洗浄し、溶媒を濃縮した。組
成物をベンゼンより再結晶して9−ピロリジノカルボニ
ルメチルカルバゾールを得た。11, 1), 190-191°C (3) Under a nitrogen stream, 5 g of 9-carboxymethylcarbazole and 1.74 g of pyrodine were mixed with dimethylformamide 4
Dissolve in 0 ml and add 3, 5 diethyl cyanophosphate to this.
3 g of N. Add 15 ml of N-dimethylformamide solution, then add 4. triethylamine. Add 19 g,
Stirred at room temperature for 14 hours. Water was added to the mixture and extracted with ethyl acetate. The mixture was washed successively with a 5% hydrochloric acid solution, an aqueous sodium hydrogen solution, and a saturated saline solution, and the solvent was concentrated. The composition was recrystallized from benzene to obtain 9-pyrrolidinocarbonylmethylcarbazole.
m.p. 207〜209℃ 上記と同様にして、以下の化合物を得た。m. p. 207~209℃ The following compounds were obtained in the same manner as above.
9−ピペリジノカノしボニルメチルカルバゾールm.p
. 166〜168℃
9−(4−メチルピペリジノ)カルボニルメチルカルバ
ゾール
m.p. 183〜186℃
9−モルホリノカルボニルメチルカルバゾールm.p.
256〜258℃
9−(2−トリフルオロメチノしフェニJし)カルバモ
イルメチルカルバゾール
m.p. 234〜236℃9-piperidinocanocarbonylmethylcarbazole m. p
.. 166-168°C 9-(4-methylpiperidino)carbonylmethylcarbazole m. p. 183-186°C 9-morpholinocarbonylmethylcarbazole m. p.
256-258°C 9-(2-trifluoromethinophenol)carbamoylmethylcarbazole m. p. 234-236℃
Claims (1)
低級アルキル基で置換された1−ピペリジノ基、1−ピ
ペラジノ基、1−モルホリノ基またはトリフルオロメチ
ルアニリノ基を示す。]で表わされるカルバゾール誘導
体。(1) Formula ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ [In the formula, R is 1-pyrrolidino group, 1-piperidino group,
Indicates a 1-piperidino group, 1-piperazino group, 1-morpholino group or trifluoromethylanilino group substituted with a lower alkyl group. ] A carbazole derivative represented by.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2044774A JPH03251565A (en) | 1990-02-26 | 1990-02-26 | Carbazole derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2044774A JPH03251565A (en) | 1990-02-26 | 1990-02-26 | Carbazole derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH03251565A true JPH03251565A (en) | 1991-11-11 |
Family
ID=12700762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2044774A Pending JPH03251565A (en) | 1990-02-26 | 1990-02-26 | Carbazole derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH03251565A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002265446A (en) * | 2001-03-06 | 2002-09-18 | Jsr Corp | New carbazole derivative and chemically amplified radiation-sensitive resin composition |
-
1990
- 1990-02-26 JP JP2044774A patent/JPH03251565A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002265446A (en) * | 2001-03-06 | 2002-09-18 | Jsr Corp | New carbazole derivative and chemically amplified radiation-sensitive resin composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU611984B2 (en) | Novel sulfhydryl containing tricyclic lactams and their pharmacological methods of use | |
KR100345942B1 (en) | 1-phenylpyrazole compounds or optical isomers therof, and pharmaceutical compositions for treatment of hyperuricacidemia and gout comprising said compounds as effective ingredient | |
EP0296975A1 (en) | 2,2-Dimethyl-3-chromanol derivatives, process of their preparation and pharmaceutical compositions containing them | |
EP2880038A1 (en) | Protein kinase inhibitors | |
JPS5849366A (en) | 3,4-dihydrocarbostyril derivative | |
JPS62265278A (en) | N-(phenyl) or n-(phenylcyclopropyl)-2, 5-dihydro-2-oxo -4-((substituted phenyl)amino)-3-furan carboxyamido derivative | |
JPH0393787A (en) | Pharmaceutical agent having viral action or antiviral action, phospholipid derivative and method of its preparation | |
EP0515668A1 (en) | OXO-TETRAHYDROPYRIDAZINYL-PYRAZOLO 4,3-b]-1,4-BENZOXAZINES | |
JPH03251565A (en) | Carbazole derivative | |
US4857527A (en) | Morpholine containing pyridine compounds, compositions and use | |
CA1265159A (en) | Gem-dihalo-1,8-diamino-4-aza-octanes | |
CN110372614B (en) | Tetrahydroquinoxaline compound, preparation method and application thereof | |
US5360909A (en) | Phenoxyacetic acid compounds and medical preparations containing them | |
FR2478099A1 (en) | PROCESS FOR THE PREPARATION OF 5,11-DIHYDRO-6H-PYRIDO- (2,3-B) (1,4) -BENZODIAZEPINE-6-ONE DERIVATIVES AND PRODUCTS AND INTERMEDIATES THUS OBTAINED | |
GB2143814A (en) | Quinazolines | |
CA2166032A1 (en) | 1-oxo-2-(phenylsulfonylamino)pentylpiperidine; process for preparing them and their use as therapeutic agents | |
US4293553A (en) | 1-Phthalazone derivatives, and use thereof | |
US3236873A (en) | 1, 6-dimethanesulfonyl mannitol compounds | |
CN112010774A (en) | FXIa coagulation factor inhibitor, and pharmaceutical composition and application thereof | |
JPH03251564A (en) | Dimethylcarbazole derivative | |
CA1076577A (en) | Process for preparing hydrazinopyridazine derivatives | |
WO1983002944A1 (en) | NOVEL s-TRIAZOLEAD1,5-aBDPYRIMIDINE DERIVATIVES | |
JPH051063A (en) | Pyrazolopyridine derivative and its production | |
JP2000502676A (en) | Transapobincamate derivatives as drugs | |
JPS5946944B2 (en) | Method for producing 5-bivaloyloxy-5-(1-phenylethyl)valpituric acid |